Verséa Discovery, Inc. Announces the Official Launch of mescreen™ Research Validator – a Revolutionary Mitochondrial Compound Assessment Platform
August 27 2024 - 6:00AM
Business Wire
Verséa Discovery, Inc., a Florida-based company dedicated to
advancing scientific research and development in the area of
personalized and precision medicine, has announced the official
launch of mescreen™ Research Validator.
The mescreen™ Research Validator is a groundbreaking,
proprietary compound assessment platform that harnesses
mitochondrial function and dynamics to generate critical data,
supporting the development, formulation, and clinical validation of
customers' supplements, nutraceuticals, pharmaceuticals, biologics,
and medical devices.
By utilizing patented optimized bioassay, imaging, and
machine-learning process, the mescreen™ Research Validator delivers
valuable insights into mitochondrial efficiency and the clinical
effects of various test materials in-vitro and in-vivo.
Research utilizing Verséa's proprietary machine learning system
has analyzed over 60 FDA-approved compounds and probes known to
impact mitochondrial function and dynamics. These studies have
demonstrated the platform's capability to detect changes in
mitochondrial function and structure upon the introduction of test
materials into the assay. The platform is also able to detect
changes in mitochondrial function when therapeutics, interventions
and lifestyle changes were introduced to and implemented by
subjects.
"We are thrilled to bring this groundbreaking technology to
market," said Stephen Porada, the President of Verséa Discovery,
Inc. "mescreen™ Research Validator has tremendous potential to help
companies validate or optimize the performance of their bioactive
molecules, ingredients or physical interventions being targeted for
commercial product development."
Dr. Hemal Patel, Chief Scientific Advisor of Verséa Discovery,
Inc., added, "In addition to this important advancement, we are
currently developing the mescreen™ Personalized Mitochondrial
Efficiency Test, which aims to provide individuals with a
comprehensive energetic profile. This test will utilize a 12-matrix
panel to accurately quantify core functions and dynamics providing
important data and information related to one’s mitochondrial
efficiency. Our commitment to enhancing mitochondrial health will
empower individuals to better understand and improve their
well-being."
To gain insight into the science behind mescreen™ Research
Validator and explore how it can benefit your research and product
development efforts, please contact Verséa Discovery, Inc. at
discovery@versea.com or call 1-800-397-0670.
About Verséa Discovery, Inc.
Verséa Discovery, Inc., headquartered in Tampa, FL, is a U.S.
company committed to advancing scientific research and development
in personalized and precision medicine. Operating as a strategic
business unit of Verséa Health, Inc., the company specializes in
developing innovative solutions that deliver critical insights into
health at the cellular and mitochondrial levels. To learn more
visit Verséa Discovery webpage.
Disclaimer: mescreen™ is for research use only and is not
intended to diagnose, treat, or cure disease. You should not change
medications, diet, exercise regimens, or other related health
activities without consulting your physician. mescreen™ has not
been reviewed by the Food and Drug Administration. mescreen™ is a
trademark of Verséa Health, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240827470287/en/
Verséa Discovery, Inc. Stephen Porada, President sp@versea.com
1-800-397-0670